

CLAIMS

1. A method for inducing the differentiation of a regulatory T cell and/or promoting the proliferation of a regulatory T cell, which comprises stimulating a GPI-anchored protein existing on the surface of an immunocyte other than CD52 with an agonist of the protein.
2. The method according to claim 1, wherein the GPI-anchored protein is involved in T cell activation.
3. The method according to claim 1, wherein the GPI-anchored protein is selected from the group consisting of CD55, CD59, and CD48.
4. The method according to claim 1, wherein the agonist is an anti-GPI-anchored protein antibody or a fragment thereof.
5. The method according to claim 4, wherein the anti-GPI-anchored protein antibody is a humanized antibody or a human antibody.
6. The method according to any one of claims 1 to 5, which further comprises stimulating CD3 existing on the surface of an immunocyte with a CD3 agonist.
7. The method according to claim 6, wherein the CD3 agonist is an anti-CD3 antibody or a fragment thereof.
8. The method according to claim 7, wherein the anti-CD3 antibody is a humanized antibody or a human antibody.
9. The method according to any one of claims 1 to 8, wherein the immunocyte is a T cell.
10. The method according to claim 9, wherein the immunocyte is a peripheral blood mononuclear cell.
11. The method according to any one of claims 1 to 10, wherein stimulation of the immunocyte with the CD3 agonist and stimulation of the immunocyte with the GPI-anchored protein agonist are performed *ex vivo*.
12. The method according to any one of claims 1 to 10, wherein stimulation of the

immunocyte with the CD3 agonist and stimulation of the immunocyte with the GPI-anchored protein agonist are performed *in vivo*.

13. A regulatory T cell, which is obtained by inducing differentiation and/or promoting proliferation by the method according to any one of claims 1 to 10.

14. A cell-containing product, which contains a regulatory T cell that is obtained by inducing differentiation and/or promoting proliferation by the method according to claims 1 to 10.

15. A pharmaceutical composition for immunosuppression, which contains a regulatory T cell that is obtained by inducing differentiation and/or promoting proliferation by the method according to any one of claims 1 to 10.

16. The pharmaceutical composition according to claim 15 for preventing or treating autoimmune diseases, allergic diseases, or immune responses to transplantation.

17. A method for preparing a humanized antibody or an antibody against a GPI-anchored protein other than CD52, which is a drug having effects of inducing the differentiation of a regulatory T cell and/or promoting the proliferation of a regulatory T cell.

18. The method according to claim 17, wherein the GPI-anchored protein is selected from the group consisting of CD55, CD59, and CD48.

19. A method for screening for a drug having the effects of inducing the differentiation of and/or promoting the proliferation of a regulatory T cell using as an index the interaction with a GPI-anchored protein other than CD52, which comprises causing a cell expressing a GPI-anchored protein other than CD52 to come into contact with a candidate compound and then detecting their interaction or a response of the GPI-anchored protein to stimulation.

20. The method according to claim 19, wherein the GPI-anchored protein is selected from the group consisting of CD55, CD59, and CD48.

21. A regulatory T cell derived from a human immunocyte, which is obtained by

stimulating an immunocyte collected from a patient's body or another human's body, specifically by stimulating a GPI-anchored protein existing on the surface of the immunocyte, other than CD52, with an agonist of the protein, so as to induce differentiation into a regulatory T cell and to promote the proliferation of the regulatory T cell.

22. The cell according to claim 21, wherein the GPI-anchored protein is selected from the group consisting of CD55, CD59, and CD48.

23. The regulatory T cell according to claim 21 or 22, which is obtained by, in addition to stimulating the collected immunocyte with the agonist, further stimulating the immunocyte with a CD3 agonist, so as to induce the differentiation into a regulatory T cell and promote the proliferation of the regulatory T cell.

24. A method for producing a regulatory T cell derived from a human immunocyte, which comprises stimulating an immunocyte collected from a patient's body or another human's body, specifically by stimulating a GPI-anchored protein existing on the surface of the immunocyte, other than CD52, with an agonist of the protein, so as to induce the differentiation into a regulatory T cell and promote the proliferation of the regulatory T cell.

25. The method according to claim 24, wherein the GPI-anchored protein is selected from the group consisting of CD55, CD59, and CD48.

26. The method for producing a regulatory T cell according to claim 24 or 25, which further comprises stimulating the collected immunocyte with a CD3 agonist in addition to stimulating the collected immunocyte with the agonist.

27. A pharmaceutical composition for inducing the differentiation of and/or promoting the proliferation of a regulatory T cell, which contains an agonist of a GPI-anchored protein other than CD52 as an active ingredient.

28. The pharmaceutical composition according to claim 27, wherein the GPI-anchored protein is involved in T cell activation.

29. The pharmaceutical composition according to claim 27, wherein the GPI-anchored protein is selected from the group consisting of CD55, CD59, and CD48.
30. The pharmaceutical composition according to claim 27, wherein the agonist is an anti-GPI-anchored protein antibody or a fragment thereof.
31. The pharmaceutical composition according to claim 30, wherein the antibody is a humanized antibody or a human antibody.
32. The pharmaceutical composition according to claim 27, which further contains a CD3 agonist.
33. The pharmaceutical composition according to claim 32, wherein the CD3 agonist is an anti-CD3 antibody or a fragment thereof.
34. The pharmaceutical composition according to claim 33, wherein the anti-CD3 antibody is a humanized antibody or a human antibody.
35. The pharmaceutical composition according to any one of claims 27 to 34 for preventing or treating autoimmune diseases, allergic diseases, or immune responses to transplantation.